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Previous studies have shown frequent mutations in the BRAF (V-raf murine sarcoma viral oncogene homolog B1)
or NRAS (neuroblastoma RAS viral [V-ras] oncogene homolog) genes in cutaneous melanoma, but the relationship
between these alterations and tumor cell proliferation has not been examined in human melanoma. In our study of
51 primary nodular melanomas and 18 paired metastases, we found mutations in BRAF (codon 600, previously
denoted 599) in 15 primary tumors (29%) and eight metastases (44%). The ﬁgures for NRASmutations were 27% and
22%, respectively. Mutations in BRAF and NRAS genes were mutually exclusive in all but one case, and were
maintained from primary tumors through their metastases. Mutations, however, were not associated with tumor cell
proliferation by Ki-67 expression, tumor thickness, microvessel density, or vascular invasion, and there were no
differences in patient survival. Although BRAF and NRAS mutations are likely to be important for the initiation and
maintenance of some melanomas, other factors might be more significant for proliferation and prognosis in sub-
groups of aggressive melanoma.
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Several genes and signalling cascades, including the RAS–
RAF–MEK–ERK–MAP kinase pathway, have been implicat-
ed in the pathogenesis of cutaneous melanoma. In a pre-
vious study, a high frequency of BRAF mutations (66%) was
found in a limited number of melanoma specimens (Davies
et al, 2002), and subsequent studies have supported these
findings (Brose et al, 2002; Dong et al, 2003; Kumar et al,
2003a; Yazdi et al, 2003; Houben et al, 2004). A significantly
lower frequency of mutations in BRAF was reported in me-
lanomas from sites with no or minimal sun exposure, as well
as sites with evidence of chronic sun damage (Maldonado
et al, 2003). In benign nevi, frequent BRAF mutations (71%–
82%) have been described, suggesting an early role of this
pathway in the development of some melanomas (Dong
et al, 2003; Govindarajan et al, 2003; Pollock et al, 2003;
Yazdi et al, 2003; Kumar et al, 2004), along with other fac-
tors (Arbiser, 2003). Also, mutations in NRAS have been
reported in 5%–33% of melanoma cases (Demunter et al,
2001; Omholt et al, 2002; Houben et al, 2004). Since the
relationship between mutations in BRAF or NRAS and
tumor cell proliferation has not been examined in human
melanoma, we studied these alterations in 51 nodular me-
lanomas and 18 paired metastases, with a focus on tumor
cell proliferation by Ki-67 expression, other markers of ag-
gressive tumors, and prognosis. Our findings support that
BRAF or NRAS mutations are present in a subgroup of cu-
taneous melanoma and subsequent metastases, but there
was no apparent association with tumor cell proliferation or
patient outcome.
Results
Mutations in BRAF and NRAS Mutations in BRAF were
found in 15 of 51 primary tumors with successful amplifi-
cation (29%), compared with eight of 18 paired metastases
(44%) (difference not significant) (Table 1, Fig 1). Of the
primary tumors with mutations, 13 carried the T1799A
(V600E) nucleotide change, and in two cases the GT1798–
99AA (V600L) mutation was present. The mutation status
was similar in primary tumors and metastases. Thus, in 17
cases with paired primary melanoma and metastasis, and in
which BRAF status had been successfully determined (in
case #24–372, the primary tumor could not be amplified), 6
primaries were found to be mutated, and all corresponding
metastases had a mutation in BRAF (100%). Conversely, in
11 patients without BRAF mutations in the primary tumor,
only two cases with a mutation (18%) were found in paired
metastases. This difference was statistically significant
(p¼0.002, Fisher’s exact test). By using a pairwise com-
parison, including the 17 pairs with complete information on
BRAF, no significant difference was present for the BRAF
status comparing primary tumors and metastases (Mc
Nemar’s test, p¼ 0.5). In 15 patients with BRAF mutation
in the primary tumor, metastases at diagnosis were present
in two cases (13%), compared with 1 of 36 (3%) of BRAF
mutation-negative tumors (p¼ 0.14).1These authors contributed equally.
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Table I. BRAF and NRAS mutations in primary melanomas and paired metastases, in addition to CDKN2A promoter methylation
and point mutations, tumor thickness, anatomic site, age, sex, status at last follow-up, and length of follow-up (months)
Case #
BRAF
—p
BRAF
—m
NRAS
—p
NRAS
—m
NRAS
—p
NRAS
—m
CDKN2A
—p
Tumor
thickness
(mm)
Anatomic
site Age Sex Status FUExon 15 Exon 15 Exon 1 Exon 1 Exon 2 Exon 2
methyl—
mut
1–84 na — na — wt — np—1 16.0 3 55 F 2 2
2–88 T4A — G4A — wt — np—1 2.8 3 85 M 3 23
3–120 wt — wt — wt — np—1 1.7 3 28 F 1 161
4–157 T4A T4A wt wt wt wt np—1 5.4 1 80 M 2 7
5–179 wt wt wt wt A4G A4G np—1 3.7 3 47 M 1 142
6–221 wt — wt — C4A — np—1 1.5 2 63 M 2 33
7–234 wt — wt — wt — np—1 1.7 3 63 F 1 117
8–257 wt — wt — A4G — np—1 3.0 3 84 F 3 21
9–258 wt wt wt wt wt wt np—1 4.6 2 40 M 2 55
10–259 T4A — wt — wt — np—1 3.7 2 69 M 2 70
11–260 wt — wt — wt — np—1 1.6 3 69 M 3 109
12–261 T4A — wt — wt — np—1 1.9 3 53 F 1 109
13–262 T4A — wt — wt — np—1 2.7 2 52 M 1 109
14–264 wt — wt — AG4CA — np—1 4.0 1 82 F 2 17
15–265 wt wt wt na A4G A4G 2—1 4.7 2 69 M 2 35
16–271 na — na — na — na—1 3.8 3 67 F 3 104
17–275 wt — wt — wt — 1—1 3.0 3 80 M 2 15
18–277 wt — wt — wt — 1—1 2.7 3 47 M 1 101
19–358 wt T4A wt wt wt wt 1—1 7.0 3 38 M 1 75
20–363 wt wt wt wt wt wt 1—1 5.4 1 76 F 1 73
21–319 wt wt wt wt wt wt 2—1 5.0 3 54 M 1 86
22–364 wt — wt — wt — 1—2 4.6 1 85 F 3 48
23–365 na — na — na — na—1 3.3 1 74 F 1 73
24–372 na wt na wt na wt na—1 6.8 3 80 M 2 37
25–381 T4A — wt — wt — 1—1 2.6 3 35 F 1 67
26–387 wt — wt — A4T — 2—1 1.2 2 65 F 1 65
27–396 wt — wt — wt — 2—1 4.4 1 90 F 3 50
28–401 wt — G4C — wt — 2—1 5.5 3 74 F 3 60
29–413 T4A T4A wt wt wt wt 1—1 3.7 2 71 M 2 27
30–416 wt GT4AA wt wt na wt 1—1 4.2 2 76 M 2 53
31–437 T4A — wt — wt — na—1 2.0 3 58 F 1 45
32–451 wt wt na wt wt wt na—1 9.5 3 78 M 1 40
33–453 T4A T4A wt wt wt wt na—2 7.2 2 79 M 2 23
34–455 wt — wt — wt — 1—1 12.2 1 38 M 1 39
35–459 wt — wt — wt — 1—1 5.3 2 47 M 1 39
36–463 wt — wt — wt — na—1 2.8 3 54 F 1 38
37–469 wt wt wt wt wt wt 1—1 2.4 2 39 M 2 12
38–477 wt — wt — A4G — 2—1 6.0 2 84 M 3 12
39–491 wt wt wt wt wt wt 2—1 8.5 1 88 M 2 17
40–512 na — na — na — na—1 2.7 4 41 M 1 23
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Mutations in the NRAS gene were found in 14 primary
tumors (27%), in 12 cases at codon 61 (exon 2), and in two
cases at codons 12 or 13 (exon 1). In one case (#14–264), a
novel AG4CA tandem mutation in NRAS involving codons
61–62 was detected, which, in addition to causing gluta-
mine to histidine change in the amino acid residue at codon
61, also changed glutamic acid to lysine in codon 62. Mu-
tations in NRAS were present in four of 18 metastases
(22%). In 15 pairs with complete NRAS status for both the
primary melanoma and metastasis, three primaries were
mutated, and the mutational status was identical in all pairs.
In all except one case, mutations in BRAF and NRAS
were mutually exclusive; one case carried mutations in both
genes (case #2–88). Thus, mutations in BRAF and/or NRAS
were present in 28 primary tumors (55%) and in 63% of the
paired metastases.
There were no significant associations between BRAF
mutations and vertical tumor thickness a.m. Breslow, tumor
cell proliferation as estimated by Ki-67 expression, micro-
vessel density, and vascular invasion. Primary tumors with
BRAF mutations, however, were more often ulcerated
(73%), than when compared with wild-type tumors (58%)
(p¼ 0.039). There was no difference when the frequency of
BRAF mutations was compared between head/neck me-
lanomas and other anatomic sites (p¼0.4). When looking at
NRAS mutations alone, or cases with BRAF and/or NRAS
mutations, no significant associations with clinicopatholog-
ical variables and tumor markers were found.
Among 30 cases with complete information on BRAF,
NRAS, and CDKN2A/p16 alterations (two with point muta-
tions, eight with CDKN2A/p16 promoter methylation)
(Straume et al, 2002), one single case (#33–453) showed
combined BRAF and CDKN2A/p16 point mutations. Four
cases showed CDKN2A promoter methylation combined
with NRAS mutations.
Survival analyses There was no significant association
between BRAF mutational status and recurrence-free or
cancer-specific patient survival. Further, there was no dif-
ference related to NRAS status, and no specific pattern
emerged when BRAF and NRAS status were combined.
Discussion
Mutations in BRAF and NRAS genes have been reported at
a high frequency in cutaneous melanoma (Davies et al,
2002), although not much is known about the relationship
between these alterations and tumor cell proliferation or
disease progress in established melanomas. In our study,
BRAF was mutated in 29% of the primary tumors, com-
pared with 27% for NRAS, and the mutations were mutually
Table I. Continued
Case #
BRAF
—p
BRAF
—m
NRAS
—p
NRAS
—m
NRAS
—p
NRAS
—m
CDKN2A
—p
Tumor
thickness
(mm)
Anatomic
site Age Sex Status FUExon 15 Exon 15 Exon 1 Exon 1 Exon 2 Exon 2
methyl—
mut
41–527 T4A — wt — wt — 1—1 4.6 1 74 F 3 15
42–514 GT4AA GT4AA wt wt wt wt 1—1 2.6 2 56 F 1 20
43–481 wt — wt — A4T — na—1 1.3 2 62 F 1 32
44–483 wt — wt — wt — na—1 3.0 3 42 M 1 31
45–519 wt — wt — A4G — 1—1 2.8 1 68 F 1 19
46–479 T4A — wt — wt — na—1 6.1 3 70 F 3 32
47–503 wt — wt — wt — na—1 2.7 3 61 F 1 24
48–515 wt wt wt wt C4A C4A 1—1 5.4 3 61 M 2 20
49–518 T4A — wt — wt — 1—1 2.7 2 44 F 1 20
50–522 wt — wt — wt — 1—1 6.5 1 89 F 3 19
51–526 T4A T4A wt wt wt wt 1—1 4.4 2 47 M 2 18
52–530 na — na wt na C4A na—1 2.7 3 77 F 1 17
53–538 GT4AA GT4AG wt wt wt — 1—1 13.5 2 73 M 2 4
54–540 wt — wt — wt — 2—1 5.4 2 75 M 1 13
55–541 wt — wt — wt — 1—1 4.8 3 87 F 1 13
56–311 wt — wt — C4A — na—1 3.5 3 34 M 1 89
57–341 wt — wt — A4G — 1—1 1.3 3 73 F 1 80
p, primary tumor; m, metastasis; methyl¼promoter methylation (np, not performed, na, not successfully amplified, 1, un-methylated, 2, methylated);
mut, mutation (na, not successfully amplified, 1, mutation not present, 2, mutation present); anatomical site: 1, head/neck, 2, truncus, 3, extremities, 4,
other; status, status at last follow-up (1, alive, 2, dead of disease, 3, dead of other diseases); FU, follow-up time in months, from histological diagnosis
until last control or death.
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exclusive in all but one single case. There was a high degree
of concordance between primary tumors and paired met-
astases with respect to mutations in both genes. When
combined, BRAF and NRAS genes were mutated in 55% of
the primary tumors, supporting a significant role in me-
lanoma development. There was no relationship, however,
between these mutations and tumor cell proliferation as
measured by Ki-67 expression, which has previously been
found to be a strong prognostic factor in the present me-
lanoma series (Straume et al, 2000b). Also, there was no
apparent association between BRAF/NRAS mutations and
other markers of aggressive melanoma, like vertical tumor
thickness, vascular invasion, or tumor-associated angio-
genesis as estimated by microvessel density.
All mutations in BRAF involved codon 600 (previously
599), located in the kinase activation domain. Mutations at
this codon result in a substitution of valine with either acidic
or basic residues, which probably mimics the activational
phosphorylation of adjacent residues. The valine residue at
codon 600 is identical to the corresponding positions in
RAF1 and ARAF1 (Davies et al, 2002; Yuen et al, 2002), and
is evolutionary conserved. Either type of substitution at this
residue, acidic or basic, has been shown to activate BRAF
(Kumar et al, 2003a; Pollock et al, 2003).
Most of the NRAS mutations involved codon 61, a find-
ing similar to what has been reported in other studies
(Demunter et al, 2001; Omholt et al, 2002; Houben et al,
2004). We also observed one novel tandem mutation,
which, in addition to changing codon 61, also caused an
amino acid substitution in the adjacent codon 62. Previous
reports have associated mutations in NRAS with sun ex-
posure, and recent studies have shown a reduced frequen-
cy of BRAF mutations in melanomas at sites with chronic
sun exposure or no exposure (Maldonado et al, 2003; Co-
hen et al, 2004; Edwards et al, 2004). Thus, the pattern of
BRAF and NRAS mutations might be a signature of etio-
logic factors in malignant melanoma. In this study of nodular
melanoma, there was no significant association between
BRAF or NRAS mutations and anatomic site, but other his-
tologic subtypes like superficial spreading melanoma and
lentigo maligna melanoma were not included for study.
It has been suggested that BRAF mutations are impor-
tant for tumor progression and patient prognosis (Dong
et al, 2003), since the BRAF mutational frequency was in-
creased from the radial to the vertical phase of melanoma
growth. Our present findings indicate, however, that in es-
tablished vertical growth phase melanomas of the nodular
type, there appears to be no advantage for tumor progres-
sion associated with the presence of BRAF or NRAS mu-
tations, since no correlation was found with tumor cell
proliferation, tumor thickness, or patient prognosis. Our
findings are in agreement with other recent reports on
prognosis (Maldonado et al, 2003; Omholt et al, 2003; Hou-
ben et al, 2004; Shinozaki et al, 2004). In a previous study
from our group (Kumar et al, 2003a), the duration of treat-
ment response tended to be longer in cases with BRAF
mutations, although not significant. These cases were all
progressive metastatic melanomas treated with chemother-
Figure 1
Mutation detection by SSCP and DNA sequencing. (A) SSCP analysis of mutations in exon 15 of the BRAF gene in metastasized melanomas.
Samples 19–358, 29–413, and 33–453 in lanes 1, 4, and 6 show aberrant bands due to T4A mutation in codon 600 of the BRAF gene and samples
42–514 in lane 9 shows a band shift due to GT4AA mutation in the same codon. Lanes 2, 3, 5, 7, and 8 contain samples with no mutation in exon 15
of the BRAF gene. (B) SSCP analysis of mutations in exon 2 of the NRAS gene in primary melanomas. The aberrant band in lane 4 is due to a
CAA4CGA mutation in codon 61 in sample 15–265 and the shifted band in lane 5 is due to CAA4CAC and GAA4AAA tandem mutation in codons
61 and 62. Lanes 1–3 and 6–8 contain DNA from samples without mutation in exon of the NRAS gene. (C) Part of exon 15 of the BRAF gene
sequence from melanoma case 42–514 showing GT4AA sequence change (thick line) in codon 600. (D) Part of exon 2 of NRAS gene sequence
showing AG4CA mutation in codon 61 and 62 (thick line). (E) Part of exon 15 of the BRAF gene corresponding to a wild-type sequence at and
around codon 600. (F) Part of exon 2 of the NRAS gene corresponding to a wild-type sequence at and around codon 61.
BRAF AND NRAS MUTATIONS IN CUTANEOUS MELANOMA 315125 : 2 AUGUST 2005
apy, and the results cannot be directly compared with our
present findings. The opposite was found in a different
study of metastatic melanoma (Houben et al, 2004). Thus,
our findings confirm other reports, concluding that there
appears to be no significant survival difference according to
mutation status for BRAF and NRAS in primary melanomas.
In conclusion, our findings confirm a high frequency of
BRAF or NRAS mutations in primary melanomas, and the
mutational status was consistent from the primary tumor to
corresponding metastases. Mutations in BRAF or NRAS
were not associated with tumor cell proliferation, other pro-
gression markers, or patient survival in our series of primary
nodular melanoma.
Materials and Methods
Patients and follow-up This patient series has been described
previously (Straume et al, 2000). Briefly, a population-based series
of 202 cutaneous melanomas with a pure vertical growth phase
(i.e., nodular melanomas), occurring during 1981–97, were initially
available. From this series, a subgroup of 57 cases, with data on
CDKN2A/p16 alterations from a previous study (Straume et al,
2002), were included for BRAF/NRAS studies and comparison with
CDKN2A/p16 status. This subgroup of 57 melanomas had been
randomly selected from the series of 202 cases (with no difference
in basic clinicopathologic features). Tissue from metastases was
available in 18 of the 57 patients.
Hospital records were used to obtain follow-up data, and infor-
mation about cause and date of death was obtained from The Can-
cer Registry of Norway and Statistics Norway. For the whole series
of 202 cases, complete information on patient survival, time and
cause of death was available, and 69 patients died during follow-up.
In the subset of 51 cases with data on mutations (six cases were not
successfully amplified), 18 melanoma deaths were observed during
the follow-up period. The last date of follow-up was December 31,
1999, and the median follow-up time for all survivors (total survival)
was 76 months (range 13–210). The study was conducted according
to the Declaration of Helsinki Principles and in accordance with in-
stitutional practice (Haukeland University Hospital).
Clinicopathologic variables The following variables were record-
ed: date of histologic diagnosis, sex, age at diagnosis, anatomic
site of the primary tumor, and presence of metastases at diagnosis.
The hematoxylin and eosin (HE) slides were re-examined, and the
following was included: tumor thickness (Breslow, 1970), Clark’s
level of invasion (Clark et al, 1969), microscopic ulceration, and
vascular invasion (Straume and Akslen, 1996).
Tumor specimens From the selected subgroup of primary
tumors, tumor tissue was manually dissected from uncovered
slides after microscopic examination, and DNA was isolated. This
group of tumors was previously studied for various CDKN2A/p16
alterations (Straume et al, 2002), and these data were included for
comparison, as well as information on tumor cell proliferation (Ki-
67) and microvessel density (MVD) (Straume and Akslen, 2001).
DNA extraction and SSCP (single strand conformational
polymorphism) analysis DNA was extracted from formalin-fixed,
paraffin-embedded tissue sections by incubating them in a diges-
tion buffer containing 200 mg per mL Proteinase K (Kumar et al,
2003b). Exons 11 and 15 of the BRAF gene and exons 1 and 2 of
the NRAS gene were amplified for SSCP analysis using primers as
previously described (Kumar et al, 2003b). PCR was carried out in
10 mL volume reactions containing 50 mM KCl, 0.11 mM of each
dNTP, 1 mCi [a-32P] dCTP, 0.3 U Taq DNA polymerase, 1–2 mM
MgCl2, and 0.15–0.3 mM of each primer. The temperature for PCR
was set as: denaturation at 951C for 1 min, annealing at 52–561C
(depending on exon) for 1 min, and polymerization at 721C for
1 min for three cycles followed by 27–33 cycles at the same tem-
peratures with a segment time of 30 s each (Kumar et al, 2003a, b).
Amplified products were electrophoresed on a 0.5  MDE gel in at
least three different conditions.
Sequence analysis Mutations detected by SSCP in different ex-
ons of the BRAF and NRAS genes were identified and confirmed
by direct sequencing using a Rhodamine dye terminator cycle se-
quencing kit (Big Dye; Applied Biosystems, Foster City, California).
Individual exons containing mutations were amplified by PCR. The
amplified products were purified using Sephadex micro-spin col-
umns (Amersham-Pharmacia, Uppsala, Sweden) and subjected to
26 cycles of sequencing reaction using forward or reverse primers
separately (Kumar et al, 2003a, b) The precipitated sequencing
reaction products were electrophoresed on a denaturing poly-
acrylamide gel in an automated sequencer (ABI 377, Applied Bio-
systems) and analyzed using ABI Prism and Edit View 1.0.1 soft-
ware. The sequencing data were analyzed using the Align program
in the DNA star software package.
In most communications on mutations in the BRAF gene, the
nucleotide and codon numbers (e.g., codon 599) have been based
on the NCBI gene bank nucleotide sequence NM_004333. Ac-
cording to the NCBI gene bank sequence with accession number
NT_007914, however, there is a discrepancy of one codon (three
nucleotides) in exon 1 in the sequence with accession number
NM_004333. The sequence analysis of exon 1 of the BRAF gene in
our laboratory has shown that the sequence derived from
NT_007914 is correct (Kumar et al, 2003b); the ‘‘hot spot’’ codon
is therefore denoted codon 600 instead of codon 599.
Statistics Analyses were performed using the statistical package
SPSS (Norusis, 1994). Associations between different categorical
variables were assessed by Pearson’s w2 test. Paired data were
tested by McNemar’s test. Continuous variables not following the
normal distribution were compared between two or more groups
using the Mann–Whitney U or Kruskal–Wallis H tests. Univariate
analyses of time to recurrent disease or death due to malignant
melanoma were performed using the product-limit procedure
(Kaplan–Meier method), with date of histologic diagnosis as the
starting point. Differences between categories were tested by the
log-rank test.
Regarding mutations in BRAF or NRAS, the following sub-
groups were compared (associations with other variables and out-
come): BRAF mutation positive versus negative; NRAS mutation
positive versus negative; patients with any mutations (BRAF or
NRAS) versus patients with no mutations.
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